Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Hepatitis E confirmed in Gulu
Gulu Hepatitis E has been confirmed in Odeke Sub-county in Gulu District. The District Health Educator Mr Okot Lukaki said three cases have been reported. He said a task force has been created to ensure cleanliness especially in the camps. Mr Lukaki said

New hepatitis C virus vaccines study findings reported from Research Center for Infectious Diseases
- (NewsRx.com) -- Fresh data on hepatitis C virus are presented in the report 'Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C.' According to recent research published in the journal

Hepatitis E Risk 'On the Rise'
(UN Integrated Regional Information Networks/All Africa Global Media via COMTEX News Network) -- More people are at risk of contracting the Hepatitis E virus (HEV) in the northern Uganda district of Kitgum, according to a surveillance health report. 'The

UPDATES AND COMMENTARY RSS Feed

Good News for Non-Responders to HCV Combination Therapy
A Phase 3 trial evaluating ZADAXIN® (thymalfasin) as a potential third component for Hepatitis C traditional combination therapy has just been completed. Although the data is currently being analyzed and won't be available until later in the year, the lead...

Purer, Less Costly Interferon for Hepatitis C and B Treatment
The Taiwan-based biopharmaceutical company PharmaEssentia Corp. is testing P1101, its third-generation PEG-interferon-alpha drug candidate. Because it is a longer-lasting, purer interferon that is less costly to produce, P1101 could enhance the treatment options for Hepatitis C and B....

New Technology May Help Treat Hepatitis
While pharmaceutical companies are racing to find safer, more effective treatments for viral Hepatitis C and B, physicists from Arizona have a unique perspective on accomplishing the same goal. Learn how these scientists believe the virus could be rendered harmelss...

table 4

The Normal Adult Human Liver Biopsy: A Quantitative Reference Standard

table  4.   Parallelism of Structural Profiles Within Portal Tracts


Parallelism
  Bile ducts to hepatic arteries 92% ± 8%
  Hepatic arteries to bile ducts 96% ± 5%
  Portal veins to bile ducts 95% ± 6%
  Portal veins to hepatic arteries 93% ± 8%
  Bile ducts to portal veins 72% ± 17%
  Hepatic arteries to portal veins 72% ± 19%
Characteristics
  Portal tracts without portal veins 38% ± 19%
  Portal tracts without bile ducts 7% ± 6%
  Portal tracts without hepatic arteries 9% ± 7%

NOTE. The simultaneous occurrence of interlobular bile ducts, hepatic arteries, and portal veins within portal tracts is given on a percent basis, as defined in the text. The converse also is shown, namely the percent of portal tracts lacking portal veins, interlobular bile ducts, or hepatic arteries.

Return To Article

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 04 Jul 2008